Hanmi Science Co Ltd
008930
Company Profile
Business description
Hanmi Science Co Ltd is a Korea-based holding company. The company through its subsidiaries manufactures and distributes pharmaceutical products. The company offers prescription drugs such as neuropathic pain, obesity, epilepsy, lactobacillus intestinal supplement, oral care, hair growth, anti-inflammatory, schizophrenia, smoking cessation aid, diabetes, osteoporosis, antiemetic, vaginal contraceptive, expectorants, ophthalmic, immunosuppressant, prostatism, cancer, antitussives, vitamins and nutritional supplements, constipation, dermatology, among others.
Contact
214 Muha-ro Paltan-myeon
Gyeonggi-do
Hwaseong
KORT: +82 24109114
Sector
Healthcare
Stock type
Defensive
Industry
Medical Distribution
Fiscal Year End
31 December 2026
Employees
486
Stocks News & Analysis
stocks
Navigating the ASX dividend landscape in 2026
Dividend yields are well below the 10-year average. Here’s how to navigate lower yields in 2026.
stocks
Meta stock has struggled amid AI spending concerns. Is it a buy?
Meta stock has lost ground as investors raise concern over capital expenditures and risky AI strategies.
stocks
Netflix Earnings: Strong, as expected; 2026 guidance confirms decelerating growth
We think Netflix stock is moderately overvalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,164.30 | 4.20 | 0.05% |
| CAC 40 | 8,069.17 | 6.59 | 0.08% |
| DAX 40 | 24,560.98 | 142.14 | -0.58% |
| Dow JONES (US) | 49,072.24 | 583.65 | 1.20% |
| FTSE 100 | 10,138.09 | 11.31 | 0.11% |
| HKSE | 26,585.06 | 97.55 | 0.37% |
| NASDAQ | 23,224.82 | 270.50 | 1.18% |
| Nikkei 225 | 53,454.03 | 679.39 | 1.29% |
| NZX 50 Index | 13,520.11 | 53.82 | -0.40% |
| S&P 500 | 6,873.77 | 76.91 | 1.13% |
| S&P/ASX 200 | 8,841.60 | 5.70 | 0.06% |
| SSE Composite Index | 4,116.94 | 3.29 | 0.08% |